BMS | ExChair - Scholarships @Awis_Houston | PHD @MDAndersonNews. Single cell genomics | Computational Biologist | Oncology. Crazy animal (-reptile) lover.
Cambridge, MA
Joined March 2014
- Tweets2.5K
- Following658
- Followers379
- Likes1.8K
Tapsi Kumar, PhD retweeted
Lymph node-targeted, mKRAS-specific amphiphile vaccine in #PancreaticCancer: the randomized phase 2 AMPLIFY-7P trial (@ElicioTx)
nature.com/articles/s41591-0…
Most important panel: in post surgical setting ctDNA positivity is pivotal driver of disease free survival, agnostic to vaccine
Tapsi Kumar, PhD retweeted
Here the 50+ ADCs that will be discussed at #ESMO26 next week, divided by payload class and target.
B7-H3 TOPO1i leads, with 7 different ADCs!
(Note: TiP and ePoster not included)
Tapsi Kumar, PhD retweeted
ADC drug development is accelerating. But is biomarker science keeping pace?
Nearly 50% of ADC trials require no biomarker, while most that do still rely on conventional IHC.
In our new @NatRevClinOncol review published just in time pre-#ESMO26, we propose a modular framework to bridge this gap - moving beyond target expression to the multiple biological determinants of ADC efficacy and toxicity.
Proud to lead this international effort with @BarbaraPistill2 @nedmcnamee @rreddel @VivekSubbiah and colleagues.
🔗: nature.com/articles/s41571-0…
Tapsi Kumar, PhD retweeted
An AI model trained from routine electronic health record data of 3.7 million individuals predicted cancer 1 year before clinical onset, no less promoted accuracy in detection, staging, treatment response, and prognosis
cell.com/cell/fulltext/S0092…
Tapsi Kumar, PhD retweeted
Iza-Bren is very effective (not only in TNBC) but its profile is also very chemo-like.
What’s the targeted contribution vs non-specific uptake? Iza-Bren half-life is ~1 day!
What’s the correlation with EGFR expression? HER3 expression? Co-expression of both EGFR and HER3?
Tapsi Kumar, PhD retweeted
ビッグニュースが舞い込んできました！
FDAでHER2陽性早期乳がんに対するエンハーツ(トラスツズマブ デルクステカン)が承認されました。
しかも、DB-11試験に基づく術前ハイリスク集団と、DB-05試験に基づく術後残存病変を有する集団の、両方に対して一気に適応されます。
同じように、日本での承認が待たれます。果たして術前も同時に承認されるのかがポイントになります。
fda.gov/drugs/resources-info…
Since the first phase 1 trial of T-DXd, it was clear that this drug could be transformative when taken to the curative setting. Today, the FDA approved T-DXd for the neoadjuvant or adjuvant treatment of HER2+ eBC, marking a major advancement in the field. fda.gov/drugs/resources-info…
Tapsi Kumar, PhD retweeted
A study in Nature reveals that tumour microenvironments can be decomposed into spatially organized multicellular ecosystems that can be accessed non-invasively via liquid biopsy and used to profile individual cancers and target treatments. go.nature.com/4wkkdnC
ALT This is figure 2, which shows a geospatial map of multicellular programs across cancers.
Tapsi Kumar, PhD retweeted
If you're serious about AI engineering (in 2026), then learn these 13 concepts:
1 How Vector Database Works
→ newsletter.systemdesign.one/…
2 How RAG Works
→ newsletter.systemdesign.one/…
3 Design Personal Chat Assistant
→ newsletter.systemdesign.one/…
4 LLM Concepts - A Deep Dive
→ newsletter.systemdesign.one/…
5 How to Design an AI Agent
→ newsletter.systemdesign.one/…
6 What is Reinforcement Learning
→ newsletter.systemdesign.one/…
7 LLM Evals 101
→ newsletter.systemdesign.one/…
8 Context Engineering 101
→ newsletter.systemdesign.one/…
9 AI Coding Workflow 101
→ newsletter.systemdesign.one/…
10 Agentic Patterns, Simply Explained
→ newsletter.systemdesign.one/…
11 How AI Agents Work
→ newsletter.systemdesign.one/…
12 Multi-Agent Architectures, Clearly Explained
→ newsletter.systemdesign.one/…
13 How MCP Works
→ newsletter.systemdesign.one/…
What else should make this list?
===
👋 PS - Want my System Design Playbook (for Free)?
Join my newsletter with 200K+ software engineers now:
→ newsletter.systemdesign.one/…
===
💾 Save now & repost to help others learn AI engineering.
👤 Follow @systemdesignone + turn on notifications.
Tapsi Kumar, PhD retweeted
🫁 MTAP deletions in NSCLC and EGFR.
MTAP del in 10% (n=4926). In stage IV, 83% co-occurred with drivers; EGFR in 48%.
Shorter time to osimertinib discontinuation (19.0 vs 24.9 mo; HR 1.8; p=0.01). No significant OS difference.
Acquired MTAP del at resistance in 13%. Signal of activity with PRMT5 inhibition (BMS-986504).
📖 @JTOonline
DOI 👉🏻 doi.org/10.1016/j.jtho.2025.…
#CánCare #NSCLC #EGFR #biomarkers #targetedtherapy #lcsm
Tapsi Kumar, PhD retweeted
Claude can now teach your kids any school subject like a $100/hour private tutor from Khan Academy. For free.
Here are 12 prompts that explain math, science, history, and English at any grade level in minutes:
(Save this before it disappears)
Tapsi Kumar, PhD retweeted
What a time to be alive when I have to choose between attending Brian Wolpin’s talk on Daraxonrasib + chemo in 1st line #PancreaticCancer OR @RevMedicines talk on their preclinical asset RM-055 that overcomes KRAS inhibitor resistance, BOTH at the exact same time!
#AACR26
Tapsi Kumar, PhD retweeted
Our new ADC review provides a different perspective on why ADC resistance occurs and how we can address it.
advanced.onlinelibrary.wiley…
Tapsi Kumar, PhD retweeted
Cancer immunotherapy keeps revving up. Now onto a 3rd generation of T cell engagers
sciencedirect.com/science/ar…
Tapsi Kumar, PhD retweeted
More than 430 abstracts on ADCs at #AACR26!
⬆️ Largely dominated by TOPO1i ADCs and bispecific ADCs
↗️ Dual payload ADCs are growing (36 abstracts)
↘️ Degrader Antibody Conjugates (DACs) not so much (12 abstracts)
⬇️ Limited novel ADC payload classes (<15 abstracts)
Tapsi Kumar, PhD retweeted
This 2 hour Stanford lecture shows exactly how Stanford trains it's engineers to build AI systems. It's more practical than every Claude tutorial & prompting threads you've seen.
Bookmark & give it 2 hours, no matter what. It'll be the most productive thing you do this weekend.
Tapsi Kumar, PhD retweeted
Claude Chat vs Cowork vs Code Tab vs Code CLI — what's actually different?
I used Claude Code to fact-checked every feature against official Anthropic docs and put together this comparison table.
Tapsi Kumar, PhD retweeted
Wow! Cool--> #PrecisionMedicine in action 👉Individualized mRNA vaccines evoke durable T cell immunity in adjuvant Triple-negative breast cancer #TNBC @Nature @OncoAlert
👉Individualized neoantigen mRNA vaccine in 14 patients with TNBC following surgery and after neoadjuvant or adjuvant therapy
👉11/14 patients remained relapse-free for up to six years post-vaccination.
nature.com/articles/s41586-0…
